Monday, February 05, 2018 12:20:13 PM
I’m in at $1.49 when I first did my DD on the stock. Then at, 1.10, 72, 85,and .73. Today they got some news and it’s up a dime so far today. Any upward move will depend on what they release or someone releases about them. The momentum you saw at the beginning of the year is gone. That’s not to say it won’t be back when some macro news, banking law changes, rescheduling, etc move the entire sector. Then they’ll all go up again and GBLX will benefit also.
In the mean time, upcoming catalysts are the March meeting, an earnings report, for certain. There is also a possibility of a new partnership, a deal on financing or whatever. On earnings, last quarter they announced their first revenue from Nevada. They preannounced October sales of 1/2 million and said November was tracking similarly. So , revenue growth will be great. Margins, cash flow is anybody’s guess but you can’t have those without sales. Shot term. , if that’s measured in hours or days, it can’t offer a real opinion. If you want to go out weeks and months I think up to 2. In a few quarters with Nevada and Louisiana on line I could see 4 or 5. Could it get to 10? It would need a big deal in the Life Sciences area and they’d have to get compliant with NASDAQ.
As to going down to 0.40. It could go to 0. They have no money. At least not enough to do what they want. You have to decide whether you’re an investor or a trader in the stock
Recent GBLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:15:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 06:31:48 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2023 08:18:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:12:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 12:00:24 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM